Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial
Authors:
- David DeMetsDDDavid DeMets
- Prakash DeedwaniaPDPrakash Deedwania
- Björn FagerbergBFBjörn Fagerberg
- Sidney GoldsteinSGSidney Goldstein
- Stephen GottliebSGStephen Gottlieb
- Ake HjalmarsonAHAke Hjalmarson
- John KjekshusJKJohn Kjekshus
- Finn WaagsteinFWFinn Waagstein
- John WikstrandJWJohn Wikstrand
- 1 September 2001
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 142 (3) , 502-511
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Effect of Carvedilol on Survival in Severe Chronic Heart FailureNew England Journal of Medicine, 2001
- β-Blocker Therapy for Heart FailureJAMA, 2000
- Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart FailureJAMA, 2000
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Rationale, Design, and Organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF)The American Journal of Cardiology, 1997
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Effect of propranolol after acute myocardial infarction in patients with congestive heart failure.Circulation, 1986
- Patient subsets and variation in therapeutic efficacy.British Journal of Clinical Pharmacology, 1982
- A Randomized Trial of Propranolol in Patients With Acute Myocardial InfarctionJAMA, 1982